News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Cambridge Heart’s Alternans Test Gains Additional Reimbursement Acceptance; CareFirst Blue Cross/Blue Shield Issues Medical Policy For MTWA Testing
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Cambridge Heart, Inc. (OTCBB: CAMH) today announced that CareFirst Blue Cross/Blue Shield has issued a medical policy providing coverage of its Microvolt T-Wave Alternans (MTWA) Test.
Twitter
LinkedIn
Facebook
Email
Print